Literature DB >> 8959852

Mycophenolate mofetil in patients with acute renal failure: evidence of metabolite (MPAG) accumulation and removal by dialysis.

B Zanker1, S Schleibner, H Schneeberger, M Krauss, W Land.   

Abstract

Pharmacokinetics of mycophenolic acid (MPA) was analyzed in eight patients with post-transplant acute renal failure. Furthermore, the effect of hemodialysis upon blood levels of MPA and its major metabolite, MPA glucuronide (MPAG), was determined. The mean duration of the posttransplant renal failure was 18 days, but renal function resumed in all patients eventually. The patients were treated with 3 g/day of mycophenolate mofetil for 28 consecutive days combined with cyclosporine A, methylprednisolone, and ATG for induction therapy. In all patients, accumulation of MPAG but not of MPA was observed. MPA trough levels were in the range between 0.5 microgram/ml at day 2 and 2.3 micrograms/ml at the end of the study period. However, this concentration difference did not reach statistical significance. Trough levels of MPAG accumulated, reaching levels as high as 358 micrograms/ml. However, with increasing recovery of renal function, MPAG levels fell to a median trough concentration of 141 micrograms/ml. MPAG, but not MPA, could partially be removed from the circulation by hemodialysis treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8959852     DOI: 10.1007/978-3-662-00818-8_76

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  2 in total

1.  Pharmacokinetics of mycophenolic acid and its phenyl glucuronide metabolite in kidney transplant recipients with renal impairment.

Authors:  Jolanta Kamińska; Maciej Głyda; Joanna Sobiak; Maria Chrzanowska
Journal:  Arch Med Sci       Date:  2012-02-29       Impact factor: 3.318

Review 2.  Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury.

Authors:  A Mary Vilay; Mariann D Churchwell; Bruce A Mueller
Journal:  Crit Care       Date:  2008-11-12       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.